To investigate the relationship between maternal diabetes and neurodevelopmental outcomes in children born to Qatari mothers.
Approach:
Study Design: Retrospective population-based cohort study including full-term children born in 2017 to Qatari mothers with gestational diabetes, pre-pregnancy diabetes, or no diabetes.
Data Collection: Data retrieved from electronic medical records, assessing neurodevelopmental outcomes at age 4.
Key Findings:
23.8% of children were born to mothers with gestational diabetes mellitus (GDM).
2.7% diagnosed with pre-pregnancy diabetes.
73.5% born to non-diabetic mothers.
1.58% diagnosed with autism, 3.63% with speech delay, 0.99% with gross motor delay, and 0.97% with fine motor delay.
Higher odds of autism (OR 1.70) and speech delay (OR 1.44) in children of mothers with GDM, but not significant after adjusting for confounders.
Interpretation:
Limitations:
Retrospective design may limit causal inferences.
Potential confounding factors not fully controlled.
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
